Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ascendis
Pharma
Trial results set up BioMarin for expansion of Voxzogo
With phase 3 results that have “exceeded” its expectations, BioMarin looks set up to gain a label expansion for dwarfism drug Voxzogo.
Kevin Dunleavy
May 21, 2026 10:23am
FDA approves Ascendis' achondroplasia treatment Yuviwel
Mar 2, 2026 9:25am
BioMarin touts pipeline asset as potential Voxzogo replacement
Aug 5, 2025 11:30am
Ascendis must wait 3 more months for FDA verdict on TransCon PTH
May 14, 2024 5:36pm
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
Pfizer gets EU approval for long-acting human growth hormone
Feb 22, 2022 7:30am
